Boston, United States
Cyta Therapeutics is an early stage biotech company based in the United States, specializing in the development of proprietary therapeutics for obesity, NASH, and other liver diseases. The company is focused on leveraging a novel polymer nanoparticle delivery platform called IntelliGel, which targets the liver. Their lead program, CYTA-001, is an encapsulated potent thyromimetic, showing significant weight loss in a Diet Induced obesity-NASH animal model.
Founded in 2015, Cyta has secured seed funding and conducted research collaborations with pharmaceutical companies. They are currently seeking investment to bring their lead program into the clinic. With a strong pipeline and the ability to deliver highly potent drug assets with increased safety and efficacy, Cyta shows promise in addressing significant unmet medical needs in the field of obesity and liver diseases. The company's technological platform and pre-clinical stage offer an intriguing investment opportunity for venture capitalists interested in biotechnology and pharmaceuticals.
